Magazine Article | April 3, 2023

Companies To Watch: KaliVir Immunotherapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse

SNAPSHOT
KaliVir Immunotherapeutics is developing oncolytic viruses, based on its VET (vaccinia enhanced template) platform, to fight solid- tumor cancers intravenously. The platform employs modified viruses and transgenes to trigger several modes of action against tumors by various factors expressed in the engineered viruses. The company now has four products in preclinical development: VET3- TGI (ASP1012, licensed to Astellas) expressing IL-12 and a TFG-ß inhibitor, VET2-L2, which effects T-cell reprogramming to enhance tumor killing, and earlier-stage candidates, VET-AST2 and VET-ROG, in discovery with Astellas and Roche, respectively, with undisclosed modes of action.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: